论文部分内容阅读
目的:研究VEGF在膀胱尿路上皮癌(Bladder Urothelial Carcinoma,BUC)中表达,探讨该指标与BUC病理分级、临床分期及预后的关系。方法:对105例术后病理检查为膀胱尿路上皮癌患者的病理切片进行VEGF免疫组化染色,另外选择20例正常膀胱粘膜作为对照,将染色结果与BUC病理分级、临床分期以及预后情况进行比较分析。结果:VEGF通过影响肿瘤血管生成的相关机制,促进了膀胱尿路上皮癌的发生,进而影响其进展与预后。结论:VEGF对膀胱尿路上皮癌的临床病理诊断、治疗及预后评估具有一定的指导意义。
Objective: To investigate the expression of VEGF in bladder urothelial carcinoma (BUC) and to explore its relationship with pathological grade, clinical stage and prognosis of BUC. Methods: Totally 105 cases of pathological examination of bladder urothelial carcinoma were examined by immunohistochemical staining for VEGF. In addition, 20 cases of normal bladder mucosa were selected as control. The staining results were compared with the pathological grade, clinical stage and prognosis of BUC comparative analysis. RESULTS: VEGF promoted the development of bladder urothelial carcinoma by influencing the related mechanisms of tumor angiogenesis, thereby affecting its progress and prognosis. Conclusion: VEGF has clinical significance in the diagnosis, treatment and prognosis of bladder urothelial carcinoma.